Jon is Chair of the Securities Practice Group and one of the core members of the Life Sciences Practice Group. He represents clients in both public and privately placed equity and debt financings under the Securities Act of 1933, provides counseling for public companies with respect to the full range of securities compliance issues under the Securities Exchange Act of 1934, and advises high-technology, biotechnology, and medical device companies in numerous contractual and strategic matters.
Jon has an active international practice, representing European companies in merger and acquisition, financing, and other transactions with US and non-US companies.
He has extensive knowledge and experience in the public offering process, representing companies and underwriters in both initial and follow-on public offerings involving straight equity, debt securities, and hybrid securities, such as convertible exchangeable preferred stock, underwritten by major national, international, and regional underwriting firms with domestic and foreign tranches.
He also represents and counsels companies, both public and private, in merger and acquisition transactions, venture capital financings, and executive compensation issues.
Recognitions & Awards
- Chambers USA: Massachusetts – Corporate/M&A: Capital Markets (2010 – 2013)
- Chambers USA: Nationwide – Life Sciences: Corporate/Commercial (2010 – 2013)
- Best Lawyers in America (2006 – 2013)
- Boston Globe Magazine: Boston’s Best Lawyers in Biotechnology Law, Securities Law, and Technology Law (2007 – 2010)
- Massachusetts Super Lawyers: Securities & Corporate Finance (2004, 2006 – 2012)
- Phi Beta Kappa
Professional & Community Involvement
- Board member, National Consumer Law Center, Inc.
- Member, Audit and Finance Committee of the National Consumer Law Center, Inc.
- Member, American Bar Association
- Member, Massachusetts Bar Association
- Member, Boston Bar Association
Jon is Chair of the Securities Practice Group and one of the core members of the Life Sciences Practice Group. He represents clients in both public and privately placed equity and debt financings under the Securities Act of 1933, provides counseling for public companies with respect to the full range of securities compliance issues under the Securities Exchange Act of 1934, and advises high-technology, biotechnology, and medical device companies in numerous contractual and strategic matters.
Jon has an active international practice, representing European companies in merger and acquisition, financing, and other transactions with US and non-US companies.
He has extensive knowledge and experience in the public offering process, representing companies and underwriters in both initial and follow-on public offerings involving straight equity, debt securities, and hybrid securities, such as convertible exchangeable preferred stock, underwritten by major national, international, and regional underwriting firms with domestic and foreign tranches.
He also represents and counsels companies, both public and private, in merger and acquisition transactions, venture capital financings, and executive compensation issues.
Recognitions & Awards
- Chambers USA: Massachusetts – Corporate/M&A: Capital Markets (2010 – 2013)
- Chambers USA: Nationwide – Life Sciences: Corporate/Commercial (2010 – 2013)
- Best Lawyers in America (2006 – 2013)
- Boston Globe Magazine: Boston’s Best Lawyers in Biotechnology Law, Securities Law, and Technology Law (2007 – 2010)
- Massachusetts Super Lawyers: Securities & Corporate Finance (2004, 2006 – 2012)
- Phi Beta Kappa
Professional & Community Involvement
- Board member, National Consumer Law Center, Inc.
- Member, Audit and Finance Committee of the National Consumer Law Center, Inc.
- Member, American Bar Association
- Member, Massachusetts Bar Association
- Member, Boston Bar Association
Publications
-
Co-author,
President Obama signs the JOBS Act: Easing Capital Formation for Private Companies, Securities Alert ()
-
Co-author,
The Size of Financing Transactions, INSIGHTS: The Corporate and Securities Law Advisor ()
-
Co-author,
Important Factors That May Affect the Size of Your Financing Transaction, Life Sciences | Securities Advisory ()
-
Co-author,
SEC Proposes Rules to Require Revised Exchange Listing Standards for Compensation Committees, Securities Alert ()
-
Co-author,
The Dodd-Frank Act and Foreign Private Issuers, Securities Advisory ()
-
Co-author,
SEC Suspends Effectiveness of Proxy Access Rules, Securities Alert ()
-
Co-author,
Proxy Access Becomes a Reality, Securities Alert ()
-
Co-author,
Financial Reform Bill is Signed by President Obama, Securities Alert ()
-
SEC Expands Eligibility for Use of Forms S-3 and F-3, Securities Law Advisory ()
Speaking Engagements
-
Moderator,
Is that a Heartbeat? Taking the Pulse of the Current Financing Market,
BIO 2012 International Convention,
BIO 2012, Boston, MA
-
Moderator,
Financing Challenges for Later Stage Life Science Companies,
NEIBC Life Sciences Summit,
New England-Israel Business Council, Waltham, MA
-
Speaker,
Responding to the SEC’s New Disclosure Requirements for 2010: Tips and Strategies to Prepare for Proxy Season,
Responding to the SEC’s New Disclosure Requirements for 2010: Tips and Strategies to Prepare for Pro,
Mintz Levin, Webinar
-
Speaker,
Are You Ready to Draft Your 2009 Form 10-K and Proxy Statement?,
Mintz Levin, Webinar
-
Corporations in Crisis: The Role of the Lead Director and the Board,
Boston, MA
Newsroom
-
Seventy-One Mintz Levin Attorneys Named 2012 Massachusetts Super Lawyers and Rising Stars , ()
-
Sixty Mintz Levin Attorneys Included in The Best Lawyers in America, 2013 Edition, ()
-
Forty-One Mintz Levin Attorneys Featured in Chambers USA 2012 Guide, ()
-
Four Mintz Levin Members to Speak at 2012 BIO International Convention, ()
-
Fifty-Two Mintz Levin Attorneys Recognized as Massachusetts Super Lawyers, ()
-
Forty-Three Mintz Levin Attorneys Included in The Best Lawyers in America, 2012 Edition, ()
-
Mintz Levin Represents ImmunoGen, Inc. and Targacept, Inc. in Public Offerings Totaling Approximately $170 Million, ()
-
Thirty Four Mintz Levin Attorneys Featured in Chambers USA 2011 Guide, ()
-
Forty-Nine Mintz Levin Attorneys Recognized as Massachusetts Super Lawyers, ()
-
Thirty-Nine Mintz Levin Attorneys Included in The Best Lawyers in America, 2011 Edition, ()
-
Mintz Levin Adds Six Attorneys to Chambers USA 2010 Guide, ()
-
Webinar: Responding to the SEC’s New Disclosure Requirements for 2010: Tips and Strategies to Prepare for Proxy Season, ()
-
Mintz Levin Represents QIAGEN N.V. in Public Offering, ()
-
Forty-Eight Mintz Levin Attorneys Recognized as Massachusetts Super Lawyers, ()
-
Mintz Levin Represents Targacept Inc. in Public Offering, ()
-
Thirty-One Mintz Levin Attorneys Included in The Best Lawyers in America, 2010 Edition, ()
-
Twenty-Nine Mintz Levin Attorneys Included in The Best Lawyers in America, 2009 Edition, ()
-
Mintz Levin Represents Genelabs Technologies in $57M Deal with GlaxoSmithKline, ()
-
Forty-Six Mintz Levin Attorneys Recognized as Massachusetts Super Lawyers, ()
-
Forty-Five Mintz Levin Attorneys Recognized as Massachusetts Super Lawyers, ()
-
Twenty-Four Mintz Levin Attorneys Included in The Best Lawyers in America, 2008 Edition, ()
-
Mintz Levin Represents EnerNoc Inc. in $97 Million IPO, ()